IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · IEX Real-Time Price · USD
0.741
+0.001 (0.16%)
Jul 2, 2024, 3:36 PM EDT - Market closed
IceCure Medical Revenue
IceCure Medical had revenue of $3.26M in the twelve months ending March 31, 2024, with 7.02% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $743.00K with 4.65% year-over-year growth. In the year 2023, IceCure Medical had annual revenue of $3.23M with 4.67% growth.
Revenue (ttm)
$3.26M
Revenue Growth
+7.02%
P/S Ratio
10.89
Revenue / Employee
$45,944
Employees
71
Market Cap
35.53M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 3.23M | 144.00K | 4.67% |
| Dec 31, 2022 | 3.09M | -1.05M | -25.45% |
| Dec 31, 2021 | 4.14M | 270.00K | 6.98% |
| Dec 31, 2020 | 3.87M | 2.24M | 137.74% |
| Dec 31, 2019 | 1.63M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nortech Systems | 138.66M |
| Owlet | 58.02M |
| Retractable Technologies | 40.20M |
| Atara Biotherapeutics | 34.70M |
| DarioHealth | 19.04M |
| Curis | 9.81M |
| Cyclo Therapeutics | 1.13M |
ICCM News
- 1 day ago - U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes - PRNewsWire
- 14 days ago - IceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024 - PRNewsWire
- 20 days ago - Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal Function - PRNewsWire
- 4 weeks ago - FDA to Convene Advisory Panel for Review of IceCure's De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025; Aligns with Commercial Readiness Plan - PRNewsWire
- 5 weeks ago - IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024 - PRNewsWire
- 6 weeks ago - IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024 - PRNewsWire
- 6 weeks ago - IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company Showcase - PRNewsWire
- 2 months ago - Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally - PRNewsWire